GMAB News and Press, Genmab A/S From 11/03/22

Genmab ( GMAB ) on Thursday raised its 2022 revenue guidance on the back of a positive foreign exchange rate impact on its royalty revenue and strong net sales of cancer drug Darzalex. The Danish biotech now expects 2022 revenue to be in the range of DKK 13.5B to DKK ...

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody ® -CD3xCD20) in a variety of treatment settings and hematologic malignancies Four oral presentations highlighting data evaluating epcorit...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the market volatility of 2022 opened doors for intriguing discounts, investors may want to consider allocating some of their funds toward undervalued biotech stocks. Fundamentally, the underlying industry represents t...

Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application (MAA) for epcoritamab submitted by AbbVie The submissions are support...

Summary Legend Biotech's Carvykti was approved this year for the treatment of fourth and fifth-line-plus multiple myeloma. Carvykti is partnered with J&J, and the launch is off to a strong start despite supply challenges, thanks to the outstanding CARTITUDE-1 trial data. L...

Genmab ( GMAB ) has announced Q3 worldwide net trade sales of $2.05B for Darzalex (daratumumab) anti-cancer monoclonal antibody medication, compared with $1.99B generated in Q2 . Net trade sales were USD 1.09B in the U.S. and USD 955M in the rest of the world. Genmab (...

Summary Investors are flocking to USD, and most foreign currencies are now weak. On the surface, investment implications seem slight, but it is quite the contrary. This article will highlight the current market implications and ways that a strong USD influences foreign assets....

Summary As it successfully transitioned into a commercial-stage operator, Seagen is enjoying great progress. The four drugs powering Seagen's marketed portfolio are generating robust revenue growth. Meanwhile, various catalysts like the recent LAVA deal would deliver much long...

Summary Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the Nasdaq Exchange at a pre-money equity value of $834 million. Simcere Pharma of Nanjing announced a $507 million out-licensing to Spain’s Almirall for ex-China rights to ...

-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will Leverage its Leadership in Women’s Cancer in China to Commercialize and ...